Drug intelligence / Profile preview

HRS-7172

Development stage: Phase 2
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HRS-7172 is a novel, orally administered small molecule inhibitor developed as an anti-tumor agent targeting advanced solid tumors harboring RAS mutations or amplifications. It is currently being evaluated in a Phase I clinical trial to assess its safety, tolerability, and pharmacokinetics in this patient population. While detailed molecular targets have not been publicly disclosed, it is described as a likely RAS inhibitor, suggesting direct or indirect action on RAS proteins or their associated signaling pathways.

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on HRS-7172.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-7172.

Explore the full profile